N-methyl-D-aspartate antagonists and working memory performance: comparison with the effects of scopolamine, propranolol, diazepam, and phenylisopropyladenosine.
The effects of the competitive N-methyl-D-aspartate (NMDA) antagonists CPP (5 & 10 mg/kg) and NPC 12626 (25 & 40 mg/kg) and the noncompetitive NMDA antagonists phencyclidine (1, 3, & 6.25 mg/kg) and MK 801 (0.1 & 0.2 mg/kg) on performance of rats on a nonspatial delayed matching-to-sample working memory task were evaluated. At the highest dose, each NMDA antagonist reduced choice accuracy at all retention intervals. In contrast, the reference anticholinergic agent scopolamine selectively reduced accuracy at long retention intervals, suggesting that scopolamine but not the NMDA antagonists directly interfered with time-dependent working memory retention. Propranolol, diazepam, and phenylisopropyladenosine had little or no effect on choice accuracy, suggesting that noradrenergic, gamma-aminobutyric acid-diazepam, and adenosine receptors may be relatively unimportant for working memory performance as assessed in this task. The NMDA antagonists also differed from scopolamine in that doses of NMDA antagonists that reduced response accuracy also reduced response probability, altered bias (competitive antagonists only), and increased intertrial interval responding (noncompetitive antagonists only). It was concluded that NMDA antagonists disrupt cognitive functions including, but not limited to, those required for accurate working memory performance.
Pontecorvo
M J
MJ
Nova Pharmaceutical Corporation, Baltimore, Maryland.
Clissold
D B
DB
White
M F
MF
Ferkany
J W
JW
D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D001070:Appetitive Behavior / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D003975:Diazepam / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D008297:Male; D011939:Mental Recall / Q000187:drug effects*; D010622:Phencyclidine / Q000494:pharmacology; D010660:Phenylisopropyladenosine / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011941:Receptors, Adrenergic / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D011983:Receptors, Purinergic / Q000187:drug effects; D012153:Retention, Psychology / Q000187:drug effects*; D012601:Scopolamine / Q000494:pharmacology*
D000596:Amino Acids; D010879:Piperazines; D011941:Receptors, Adrenergic; D016194:Receptors, N-Methyl-D-Aspartate; D011983:Receptors, Purinergic; C060212:NPC 12626; D010660:Phenylisopropyladenosine; D016291:Dizocilpine Maleate; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; D011433:Propranolol; D012601:Scopolamine; D010622:Phencyclidine; D003975:Diazepam